ThirdLaw Molecular, Inc.

ThirdLaw Molecular has pioneered the development of Spiroligomer™ molecules – a new, patent-protected, therapeutic modality for targeted drug discovery.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Blue Bell, PA, USA
  • Currency USD
  • Founded 2020
  • Employees 9
  • Incorporation Type C-corp
  • Website thirdlawtx.com

Company Summary

ThirdLaw Molecular Inc. has pioneered the development of Spiroligomer™ molecules and is developing this innovative, patent-protected, therapeutic modality into a new class of more targeted medicines. The mission of the Company is to develop a revolutionary category of molecules that transforms how diseases are diagnosed and treated – more safely and effectively.

Team

  • David Owens
    Director

    David has been a Director of the Company since its founding. He is President & CEO of BiologicsMD, an early-stage drug development company, and Founding Partner of Bowman’s Tower Venture Partners. David has lead companies to successful exits (CEO, OrthogenRx, Inc. - sold to Avanos, Chief Business Officer, Novira Therapeutics, Inc. - sold to J&J), and has held senior commercial roles at King, Aventis, Genentech, Merck and Abbott.

  • Barry Arkles
    Director

    Dr. Barry Arkles is an innovator and leader in applied materials science, surface chemistry and biotechnology with notable contributions in thermoplastic composites, the NASA Space Shuttle, Contact Lenses, Interlayer Dielectrics and Metallization used in integrated semiconductor devices, and Gene Chips for DNA array analysis. Companies he founded/cofounded today generate ~$1Bn in annual revenue. He has over 100 patents and multiple awards.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free